Population pharmacokinetic parameters of vancomycin in critically ill patients

被引:98
作者
Llopis-Salvia, P.
Jimenez-Torres, N. V.
机构
[1] Hosp Ribera, Dept Pharm, Alzira Valencia 46600, Spain
[2] Univ Valencia, Dept Pharm, Hosp Univ Dr Peset, Pharm & Pharmaceut Technol Dept, Valencia, Spain
关键词
adult intensive care unit patients; Bayesian forecasting; critically ill patients; NONMEM; pharmacokinetics; population pharmacokinetics; vancomycin;
D O I
10.1111/j.1365-2710.2006.00762.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Intensive care unit patients are a highly heterogeneous population. Accurate dosing for this population requires characterization of the appropriate pharmacokinetic parameters. Objectives: To estimate population pharmacokinetic parameters of vancomycin (VAN) in adult critically ill patients and to establish the predictive performance of the resulting model. Patients and method: Fifty critically ill patients with suspected or documented infection with VAN-sensitive micro-organisms were included. Thirty patients and 234 serum concentration-time sets obtained during clinical routine monitoring were used to estimate the pharmacokinetic parameters (group A). An open bicompartimental model with intermittent intravenous administration was used to adjust the data. Data were evaluated using a nonlinear mixed effects model (NONMEN software). Forty plasma concentration-time data sets from 20 patients were used for validation using the Bayesian method (group B). Results: There was a linear relationship between creatinine clearance (Cl-cr) and VAN clearance (Cl-VAN). The inclusion of the non-renal clearance (Cl-nr) (intercept of Cl-VAN vs. Cl-cr relationship) improved the model significantly (Cl-nr 17 mL/min). The volume of distribution seems to be larger than previously reported: volume of the central compartment (V-c) was 0.41 L/kg and volume of the peripheral compartment was (V-p), 1.32 L/kg. The mean error (bias) and mean absolute error (precision) for predicting subsequent peak concentrations were -2.16 and 9.28 mg/L and for trough concentrations, -0.22 and 3.87 mg/L respectively. Conclusions: The use of population-specific pharmacokinetic parameters and Bayesian forecasting improves dosage-regimen design.
引用
收藏
页码:447 / 454
页数:8
相关论文
共 30 条
[1]   Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer [J].
Aldaz, A ;
Ortega, A ;
Idoate, A ;
Giráldez, J ;
Brugarolas, A .
THERAPEUTIC DRUG MONITORING, 2000, 22 (03) :250-257
[2]   EFFECTS OF HEPATIC-FUNCTION ON VANCOMYCIN CLINICAL-PHARMACOLOGY [J].
BROWN, N ;
HO, DHW ;
FONG, KLL ;
BOGERD, L ;
MAKSYMIUK, A ;
BOLIVAR, R ;
FAINSTEIN, V ;
BODEY, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (04) :603-609
[3]   RELATIONSHIP OF SERUM ANTIBIOTIC CONCENTRATIONS TO NEPHROTOXICITY IN CANCER-PATIENTS RECEIVING CONCURRENT AMINOGLYCOSIDE AND VANCOMYCIN THERAPY [J].
CIMINO, MA ;
ROTSTEIN, C ;
SLAUGHTER, RL ;
EMRICH, LJ .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (06) :1091-1097
[4]  
CULTER NR, 1984, CLIN PHARMACOL THER, V36, P803
[5]  
DEGATTA MDF, 1994, PHARMACOTHERAPY, V14, P196
[6]  
DUHARME MP, 1994, THER DRUG MONIT, V16, P513
[7]   VANCOMYCIN PHARMACOKINETICS, RENAL HANDLING, AND NONRENAL CLEARANCES IN NORMAL HUMAN-SUBJECTS [J].
GOLPER, TA ;
NOONAN, HM ;
ELZINGA, L ;
GILBERT, D ;
BRUMMETT, R ;
ANDERSON, JL ;
BENNETT, WM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (05) :565-570
[8]   APPLICATION OF A BAYESIAN METHOD TO MONITOR AND ADJUST VANCOMYCIN DOSAGE REGIMENS [J].
HURST, AK ;
YOSHINAGA, MA ;
MITANI, GH ;
FOO, KA ;
JELLIFFE, RW ;
HARRISON, EC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1165-1171
[9]  
ITO MK, 1993, CLIN PHARMACY, V12, P126
[10]  
JELLIFFE R, 1994, CLIN PHARMACOL THER, V55, P160